<DOC>
	<DOCNO>NCT02740777</DOCNO>
	<brief_summary>To evaluate immune non-inferiority , measure antibody response , 2-dose immunization schedule ( 0 , 6 month ) recombinant human papillomavirus virus-like particle vaccine ( type 16 18 L1 protein , yeast ) ( hereinafter refer HPV-2 vaccine ) adolescent female age 9 14 year comparison 3-dose immunization schedule ( 0 , 2 , 6 month ) young female age 18 26 year .</brief_summary>
	<brief_title>Evaluating 2-dose Immunization Schedule Human Papillomavirus ( HPV ) -16/18 Adolescent Females</brief_title>
	<detailed_description>The study plan enroll 600 adolescent female age 9 14 year 300 adult female age 18 26 year . The adolescent divide two cohort , 300 , receive either 2-dose ( 0 , 6 month ) immunization schedule 3-dose ( 0 , 2 , 6 month ) immunization schedule . The adult female group receive 3-dose ( 0 , 2 , 6 month ) immunization schedule . Each subject shall administrate studied vaccine accord either 2-dose 3-dose schedule . Immediate reaction occur 30 minute inoculation , local systematic reaction occur 0 7 day inoculation record . All adverse event ( AEs ) occur first dose administration 1 month final dose administration , well serious adverse event ( SAEs ) occur first dose administration 6 month final dose administration collect . Blood sample collect day 0 ( prior immunization ) , month 6 ( prior last injection ) , month 7 , month 12 , month 24 , month 36 . All blood sample test HPV 16- HPV 18-specific antibody titer .</detailed_description>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult group : 1826 healthy female enable provide legal identification ability understand sign Informed Consent Form n't pregnant pregnancy plan within 7 month first injection use effective contraceptive method last menstruation , agree avoid sexual activity without effective contraceptive method within 15 day injection Adolescent group : 914 healthy female enable provide legal identification guardian ability understand Informed Consent Form , participant guardian agree sign Form ( case unable sign , participant use fingerprint signature ) History HPV infection Previous administration HPV vaccine History severe allergic reaction require medical intervention ( oral throat swelling , difficulty breathing , hypotension shock ) History allergic vaccine , ingredient vaccine . History epilepsy , seizures convulsion , family history mental illness Subjects immunocompromised diagnosed suffering congenital acquire immunodeficiency , HIV infection , lymphoma , leukemia , systemic lupus erythematosus ( SLE ) , rheumatoid arthritis , juvenile rheumatoid arthritis inflammation ( JRA ) , inflammatory bowel disease autoimmune disease , administration immunosuppressant six month prior first vaccine dose . History asthma , thyroidectomy , angioneurotic edema , diabetes malignant Asplenia , functional asplenia , circumstance result asplenia splenectomy Medical diagnosis coagulation abnormality ( eg , clot factor deficiency , coagulation disorder , platelet anomaly ) obvious bruise coagulation disorder Acute disease chronic disease acute exacerbation 7 day prior vaccination Administration immunoglobulins and/or blood product within 3 month , administration live attenuate vaccine within 28 day , administration subunit inactivate vaccine within 14 day . Fever axillary temperature &gt; 37.0 Â°C vaccination During menstrual period , breastfeeding , pregnancy ( pregnancy test positive ) , plan pregnant within 7 month History hypertension , physical examination systolic blood pressure &gt; 150mmHg and/or diastolic blood pressure &gt; 100mmHg Abnormal laboratory test parameter Any clinical significant disease finding study screening , opinion Investigator may interfere study</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>